Presentation

P6.3 Two years after the tOPV ot bOPV switch: What happened to Poliovirus Type 2?

Ondrej Mach

Plenary 6 presentation

Authors

Languages

  • English

Publication year

2018

Type

Presentation

Categories

  • Global initiatives

Diseases

  • Polio

GVIRF-2018

This resource appears in the following Hot Topic page:

The resource is included in the following table:

TitleAuthorYearTypeLanguage
W9.4 Antibody Engineering: Optimization of Antibodies for CommercializationStephen Hadley2018PresentationEnglish
W9.3 Monoclonal Antibodies for Influenza Prevention, Therapy, or Vaccine Antigen DesignBruce Innis2018PresentationEnglish
W9.2 Monoclonal antibodies for rabies post-exposure prophylaxisErin Sparrow2018PresentationEnglish
W9.1 Pipeline of HIV monoclonal antibodies for prevention of HIVBarney Graham2018PresentationEnglish
W8.3 The Principle and Process of Autogenous VaccineSuphot Wattanaphansak2018PresentationEnglish
W8.2 Vaccination against bacterial diseases in farmed Atlantic salmon: experience and global applicabilityEdgar Brun2018PresentationEnglish
W8.1 Antimicrobial Resistance and VaccinesDennis Dixon2018PresentationEnglish
W7.5 Target Value PropositionJean Lang2018PresentationEnglish
W7.4 Human Hookworm Vaccine Initiative: a Public Health value proposition leading to societal impact and positive financial returnsMaria Elena Bottazzi2018PresentationEnglish
W7.3 A Hepatitis C Virus Vaccine UpdateAndrea Cox2018PresentationEnglish
W7.2 Update on RSV Vaccine and mAb developmentRuth Karron2018PresentationEnglish
W7.1 Global Vaccine Pipeline and Value PropositionDavid Kaslow2018PresentationEnglish
W6.3 Maternal and adolescents immunization - a global challengeRaymond Hutubessy2018PresentationEnglish
W6.2 Adolescent Immunization in Developing Countries: Obstacles and OpportunitiesHartono Gunardi2018PresentationEnglish
W6.1 Reaching Adolescents & Pregnant Women (Introduction)Odile Leroy2018PresentationEnglish
W5.4 Universal Influenza Vaccines and Their Role in PreparednessJennifer Gordon2018PresentationEnglish
W5.3 Epidemic Preparedness: National Security for ThailandPunee Pitisuttithum2020PresentationEnglish
W5.2 Influenza Pandemic Risk and PreparednessJohn S. Tam2018PresentationEnglish
W5.1 WHO R&D Blueprint Update: progress and PlansMartin Friede2018PresentationEnglish
W4.4 RTS,S Malaria Vaccine: Toward an understanding of the immunologic basis of protectionChristian Ockenhouse2018PresentationEnglish
W4.3 New technologies for studying human immunityLisa Wagar2018PresentationEnglish
W4.1 New Approaches to Understanding Human ImmunityAnnie Mo2018PresentationEnglish
W3.3 The Future of Pneumococcal Conjugate VaccinesKeith Klugman2018PresentationEnglish
W3.2 Rollout of Pneumococcal Conjugate Vaccine in IndiaNarendra K Arora, Pradeep Haldar2018PresentationEnglish
W3.1 2018 Status of Pneumococcal Conjugate Vaccine Use and ImpactKatherine L. O'Brien2018PresentationEnglish
W2.3 Controlled Human Infection Models and Enteric Vaccine DevelopmentBeth Kirkpatrick2018PresentationEnglish
W2.2 Subunit vaccine technologies for bacterial enteric diseases: Shigella, ETEC and nontyphoidal Salmonella vaccinesCal MacLennan2018PresentationEnglish
W2.1 An update on rotavirus vaccinesGagandeep Kang2018PresentationEnglish
W1.3 A novel vaccine technology platform Plasmid Launched Live Attenuated Virus (PLLAV) VaccinesJohan Neyts, Kai Dallmeier2018PresentationEnglish
W1.2 New Vaccine Strategies using cytomegalovirusKlaus Früh2018PresentationEnglish
W1.1 MIMIC: an in vitro model of human immunityDon Drake2018PresentationEnglish
W9 Antibody-Mediated PreventionNina Russell2018ReportEnglish
W8 Vaccines and Antimicrobial Resistance (AMR)A. A. Adeyemo2018ReportEnglish
W7 New Vaccine Pipeline: Lessons Learned and Accelerating ProgressJean-Pierre Amorij2018ReportEnglish
W6 Reaching Adolescents and Pregnant WomenOdile Leroy2018ReportEnglish
W5 Epidemic and Pandemic PreparednessMartin Friede2018ReportEnglish
W4 Immunological Principles of Vaccines and VaccinationAnnie Mo, Bernhards Ogutu2018ReportEnglish
W3 Pneumococcal Vaccines: Lessons Learned and the Road AheadHani Kim2018ReportEnglish
W1 Emerging Vaccine Strategies & TechnologiesPaula Bryant2018ReportEnglish
P7 Discussion with Thought LeadersPeter Dull2018ReportEnglish
P6.5 Research for polio policy making: Lessons learnedRoland Sutter2018PresentationEnglish
P6.4 Polio Vaccines - R&D UpdatesPeter Dull2018PresentationEnglish
P6.3 Two years after the tOPV ot bOPV switch: What happened to Poliovirus Type 2?Ondrej Mach2018PresentationEnglish
P6.2 Global tOPV withdrawal: "The Switch" experienceAlejandro Ramirez Gonzalez2018PresentationEnglish
P6.1 Intro Polio Endgame: Needs and OpportunitiesRoland Sutter2018PresentationEnglish
P6 Polio Endgame: Needs and OpportunitiesRoland SutterReportEnglish
P5.2 Evidence for Decision MakingYot Teerawattananon2018PresentationEnglish
P5.1 Development of WHO Full Public Health Value Propositions for vaccines to prevent infectious diseasesDavid Kaslow2018PresentationEnglish
P5 Evidence for Decision MakingDavid Kaslow, Robert BreimanReportEnglish
P4.3 Human Clinical Trial to Support the Development of New Vaccines: Perspective from ThailandAkanid Wapeewuttikorn2018PresentationEnglish

Added by: Angela Hwang

Added on: 2022-02-11 06:15:01

Hits: 1656

Uploaded file

P6-3Mach.pdf

Click to Download

Add resource